- Stocks
- Healthcare
- NASDAQ: APLS

Price (delayed)

$46.07

Market cap

$3.7B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.59

Enterprise value

$3.51B

The equity has surged by 93% since the previous quarter

The EPS is up by 41% since the previous quarter and by 6% year-on-year

APLS's net income is up by 36% since the previous quarter but it is down by 13% year-on-year

The company's quick ratio fell by 29% QoQ but it rose by 28% YoY

The company's debt has surged by 141% YoY

What are the main financial stats of APLS

Market
Valuations
Earnings

Shares outstanding

80.38M

Market cap

$3.7B

Enterprise value

$3.51B

Price to earnings (P/E)

N/A

Price to book (P/B)

17.06

Price to sales (P/S)

13.82

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

14.02

Revenue

$250.65M

EBIT

-$313.09M

EBITDA

-$312.23M

Free cash flow

-$165.91M

Per share
Balance sheet
Liquidity

EPS

-$4.59

Free cash flow per share

-$2.21

Book value per share

$2.7

Revenue per share

$3.33

TBVPS

$12.78

Total assets

$960.57M

Total liabilities

$756.01M

Debt

$377.73M

Equity

$204.56M

Working capital

$788.87M

Debt to equity

1.85

Current ratio

7.15

Quick ratio

6.85

Net debt/EBITDA

0.61

Margins
Efficiency
Dividend

EBITDA margin

-124.6%

Gross margin

100%

Net margin

-137.6%

Operating margin

-85.3%

Return on assets

-42%

Return on equity

-172.1%

Return on invested capital

-49.6%

Return on capital employed

-37.6%

Return on sales

-124.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Apellis Pharmaceuticals stock price performed over time

Intraday

0%

1 week

1.1%

1 month

9.85%

1 year

29.81%

YTD

-19.46%

QTD

7.36%

How have Apellis Pharmaceuticals's revenue and profit performed over time

Revenue

$250.65M

Gross profit

$250.65M

Operating income

-$213.73M

Net income

-$344.87M

Gross margin

100%

Net margin

-137.6%

APLS's operating margin has surged by 100% since the previous quarter

The company's net margin has surged by 100% QoQ

APLS's operating income has surged by 52% since the previous quarter and by 26% year-on-year

APLS's net income is up by 36% since the previous quarter but it is down by 13% year-on-year

What is Apellis Pharmaceuticals's growth rate over time

What is Apellis Pharmaceuticals stock price valuation

P/E

N/A

P/B

17.06

P/S

13.82

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

14.02

The EPS is up by 41% since the previous quarter and by 6% year-on-year

The equity has surged by 93% since the previous quarter

The P/B is 12% more than the last 4 quarters average of 15.3

How efficient is Apellis Pharmaceuticals business performance

The return on sales has surged by 100% since the previous quarter

The company's return on invested capital has surged by 88% YoY and by 51% QoQ

APLS's ROE is up by 49% QoQ and by 21% YoY

APLS's ROA is up by 49% year-on-year and by 47% since the previous quarter

What is APLS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for APLS.

How did Apellis Pharmaceuticals financials performed over time

Apellis Pharmaceuticals's total assets is 27% more than its total liabilities

Apellis Pharmaceuticals's total assets has soared by 147% YoY and by 25% from the previous quarter

APLS's total liabilities has surged by 113% year-on-year and by 14% since the previous quarter

The company's debt is 85% higher than its equity

The company's debt has surged by 141% YoY

The equity has surged by 93% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.